Rubicon Research Limited (RUBICON) — Announcement | 3 July 2026

StockFin.ai

Try Free

Rubicon Research Limited disclosed that the US FDA conducted an unannounced inspection of its newly acquired Pithampur manufacturing facility from June 29 to July 3, 2026, issuing a procedural Form 483 with two observations. The company, having integrated the facility and completed quality systems and regulatory filings within a year of acquisition, expressed confidence in resolving observations promptly and plans to ramp up commercial operations starting Q1 2027, reinforcing its compliance culture and regulatory track record.

📄 View Original Announcement (PDF)

📊 Stock Analysis — RUBICON ✨ Ask AI About This

About Rubicon Research Limited (RUBICON)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,864.53 Cr

View full RUBICON stock details →

📡 Get AI alerts when RUBICON files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RUBICON — Free

💡 Ask AI about this filing

"How does this announcement affect Rubicon Research Limited's outlook?" "What did Rubicon Research Limited announce on 3 July 2026?" "Is this positive or negative for RUBICON?"

Ask AI Free →

📊 More RUBICON filings

See all RUBICON filings →

🔥 Also filed on 3 July 2026

PRESTIGE Prestige Estates Projects Limited Announcement PROZONER Prozone Realty Limited Announcement PRUDENT Prudent Corporate Advisory Services Limited Annual Report PTL PTL Enterprises Limited Annual Report RADIOCITY Music Broadcast Limited Announcement RBLBANK RBL Bank Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RUBICON files new disclosures

Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RUBICON — Free

Free account · 2 AI queries/day